Cluster and chronic daily headache

被引:0
作者
Dodick, DW
Saper, J
机构
[1] Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA
[2] Michigan State Univ, E Lansing, MI 48824 USA
[3] Michigan Head Pain & Neurol Inst, Ann Arbor, MI USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cluster headache, although relatively uncommon, is one of the most painful primary headache disorders. Approximately 90% of affected individuals experience daily attacks for several weeks to months (cluster periods) separated by attack-free intervals lasting for months to years (remission periods). The other 10% of sufferers exhibit a more chronic pattern marked by attacks that persist for longer than 1 year with no remission or only short periods of remission. The most striking feature of cluster headache is its circadian and circannual periodicity, which has implicated the hypothalamic pacemaker (the suprachiasmatic nucleus) in the pathogenesis of the disorder. The unique attack profile of cluster headache mandates the use of rapid-acting symptomatic therapy, such as oxygen or subcutaneous sumatriptan. Preventive treatment is two-pronged and consists of transitional treatment, usually with prednisone, to produce rapid suppression of attacks, and maintenance treatment (typically with verapamil) for the expected duration of the cluster period. Chronic daily headache (CDH) is defined as a headache that occurs for at least 15 days per month and for at least 4 hours per day. The prevalence of CDH is only 4% in the general population but is as high as 80% in headache clinic populations. More than three quarters of patients with CDH have chronic (transformed) migraine. The pathophysiologic mechanisms of CDH remain undetermined. Pharmacotherapy is aimed at relieving daily pain and periodic superimposed acute migraine attacks. Aggressive treatment is required for rebound syndromes, and hospitalization is sometimes required for particularly difficult cases.
引用
收藏
页码:S31 / S37
页数:7
相关论文
共 49 条
[1]   DIHYDROERGOTAMINE NASAL SPRAY IN THE TREATMENT OF ATTACKS OF CLUSTER HEADACHE - A DOUBLE-BLIND TRIAL VERSUS PLACEBO [J].
ANDERSSON, PG ;
JESPERSEN, LT .
CEPHALALGIA, 1986, 6 (01) :51-54
[2]   Oral zolmitriptan is effective in the acute treatment of cluster headache [J].
Bahra, A ;
Gawel, MJ ;
Hardebo, JE ;
Millson, D ;
Breen, SA ;
Goadsby, PJ .
NEUROLOGY, 2000, 54 (09) :1832-1839
[3]   Molecular aspects of headaches and migraines - 7th International Headache Research Seminar - Copenhagen, Denmark, 22-24 November 1996 [J].
Edvinsson, L ;
Olesen, J .
MOLECULAR MEDICINE TODAY, 1997, 3 (05) :191-193
[4]  
EKBOM K, 1993, ACTA NEUROL SCAND, V88, P63
[5]   TREATMENT OF ACUTE CLUSTER HEADACHE WITH SUMATRIPTAN [J].
EKBOM, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) :322-326
[6]   PREVALENCE OF MIGRAINE AND CLUSTER HEADACHE IN SWEDISH MEN OF 18 [J].
EKBOM, K ;
AHLBORG, B ;
SCHELE, R .
HEADACHE, 1978, 18 (01) :9-19
[7]   LITHIUM FOR CLUSTER HEADACHE - REVIEW OF THE LITERATURE AND PRELIMINARY-RESULTS OF LONG-TERM TREATMENT [J].
EKBOM, K .
HEADACHE, 1981, 21 (04) :132-139
[8]   CLUSTER HEADACHE ATTACKS TREATED FOR UP TO 3 MONTHS WITH SUBCUTANEOUS SUMATRIPTAN (6 MG) [J].
EKBOM, K ;
KRABBE, A ;
MICELLI, G ;
PRUSINSKI, A ;
COLE, JA ;
PILGRIM, AJ ;
NORONHA, D .
CEPHALALGIA, 1995, 15 (03) :230-236
[9]   LOW BIOLOGICAL AVAILABILITY OF ERGOTAMINE TARTRATE AFTER ORAL DOSING IN CLUSTER HEADACHE [J].
EKBOM, K ;
PAALZOW, L ;
WALDENLIND, E .
CEPHALALGIA, 1981, 1 (04) :203-207
[10]   TREATMENT OF CLUSTER HEADACHE - A DOUBLE-BLIND COMPARISON OF OXYGEN-UPSILON AIR INHALATION [J].
FOGAN, L .
ARCHIVES OF NEUROLOGY, 1985, 42 (04) :362-363